Redhill Biopharma Ltd (NASDAQ:RDHL) — Stock Price
Redhill Biopharma Ltd (NASDAQ:RDHL) is currently trading at $0.58 USD, down 3.97% today. Over the past 52 weeks, shares have ranged between $0.58 and $2.52. This page tracks Redhill Biopharma Ltd's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see RDHL market cap overview.
Redhill Biopharma Ltd (RDHL) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Redhill Biopharma Ltd's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Redhill Biopharma Ltd Income Statement — Revenue, Profit & Earnings by Year
Redhill Biopharma Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $286.00K | $8.04 Million | $6.53 Million | $61.80 Million | $85.76 Million |
| Cost of Revenue | — | $3.19 Million | $3.46 Million | $33.34 Million | $49.41 Million |
| Gross Profit | $286.00K | $4.85 Million | $3.07 Million | $28.46 Million | $36.35 Million |
| Research & Development | $2.02 Million | $1.59 Million | $3.53 Million | $7.28 Million | $29.50 Million |
| SG&A | $6.17 Million | $14.52 Million | $28.88 Million | $54.97 Million | $76.60 Million |
| Total Operating Expenses | $8.20 Million | $19.46 Million | $-9.56 Million | $71.31 Million | $117.49 Million |
| Operating Income | $-7.91 Million | $-14.61 Million | $12.63 Million | $-42.84 Million | $-81.14 Million |
| EBITDA | $-7.65 Million | $-7.59 Million | $26.27 Million | $-22.18 Million | $-63.03 Million |
| EBIT | $-8.06 Million | $-8.21 Million | $24.28 Million | $-30.34 Million | $-81.18 Million |
| Interest Expense | $19.00K | $55.00K | $367.00K | $41.33 Million | $16.57 Million |
| Income Before Tax | $-8.08 Million | $-8.27 Million | $23.92 Million | $-71.67 Million | $-97.74 Million |
| Income Tax Expense | — | — | $-2.00 | $-12.42 Million | $16.57 Million |
| Net Income | $-429.00K | $-8.27 Million | $23.92 Million | $-71.67 Million | $-97.74 Million |
Redhill Biopharma Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Redhill Biopharma Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $25.34 Million | $18.04 Million | $23.05 Million | $158.87 Million | $181.19 Million |
| Total Current Assets | $6.53 Million | $11.91 Million | $16.14 Million | $85.90 Million | $89.15 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | $2.73 Million | $790.04K | $15.00K | $8.53 Million |
| Net Receivables | $2.48 Million | $3.57 Million | $3.29 Million | $37.88 Million | $32.52 Million |
| Inventory | $0.00 | $3.65 Million | $4.39 Million | $11.01 Million | $14.81 Million |
| Property, Plant & Equipment | — | — | — | — | $4.22 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $21.08 Million | $22.73 Million | $20.98 Million | $207.27 Million | $172.31 Million |
| Total Current Liabilities | $19.22 Million | $22.22 Million | $19.24 Million | $197.45 Million | $81.47 Million |
| Long-term Debt | — | — | — | — | $83.62 Million |
| Net Debt | $-2.90 Million | $-4.26 Million | $-4.40 Million | $102.72 Million | $58.34 Million |
| Total Stockholder Equity | $4.27 Million | $-4.68 Million | $2.07 Million | $-48.40 Million | $8.88 Million |
| Retained Earnings | $-413.75 Million | $-414.80 Million | $-407.74 Million | $-433.86 Million | $-367.87 Million |
Redhill Biopharma Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Redhill Biopharma Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-9.65 Million | $-9.37 Million | $-35.82 Million | $-29.18 Million | $-65.05 Million |
| Capital Expenditures | $5.00K | $9.00K | $11.00K | $198.00K | $115.00K |
| Free Cash Flow | $-9.66 Million | $-9.38 Million | $-35.83 Million | $-29.38 Million | $-65.16 Million |
| Investing Cash Flow | $1.69 Million | $-9.00K | $3.99K | $8.30 Million | $-8.14 Million |
| Financing Cash Flow | $7.32 Million | $8.42 Million | $21.38 Million | $11.45 Million | $73.46 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $457.00K | $665.00K | $1.65 Million | $5.67 Million | $10.21 Million |
| Depreciation | $409.00K | $619.00K | $1.99 Million | $8.15 Million | $18.15 Million |
| Change in Cash | $-646.00K | $-952.00K | $-14.40 Million | $-9.51 Million | $179.00K |
Redhill Biopharma Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Redhill Biopharma Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 12, 2026 | 0.00 | 0.00 | — |
| Dec 02, 2025 | 0.00 | 0.00 | — |
| Sep 05, 2025 | -2.29 | 0.00 | — |
| Apr 10, 2025 | -4.02 | 0.00 | — |
| Mar 31, 2025 | -4.02 | 0.00 | — |
| Nov 29, 2024 | 0.00 | 0.00 | — |
| Aug 29, 2024 | -200.00 | -30.00 | -566.67% |
| Apr 08, 2024 | -0.20 | -0.03 | -566.67% |